Fluoxetine Market Overview 2024-2033 - Share, Size, Insights, Forecast

The new report published by The Business Research Company, titled Fluoxetine Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the fluoxetine market size has grown steadily in recent years. It will grow from $0.94 billion in 2023 to $0.99 billion in 2024 at a compound annual growth rate (CAGR) of 4.7%. The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.19 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=16428&type=smp

Rising Prevalence Of Mental Health Disorders Fuels Growth Of Fluoxetine Market
The rising prevalence of mental health disorders is expected to propel the growth of the fluoxetine market going forward. Mental health disorders encompass a broad range of conditions that affect cognitive, emotional, and behavioral functioning, leading to distress or impairment in daily life. Mental health disorders are rising due to a complex interplay of factors, including societal pressures, economic stresses, lifestyle changes, and increased awareness and diagnosis. Fluoxetine is used for mental health disorders because it helps to alleviate symptoms by increasing serotonin levels in the brain, which plays a crucial role in regulating mood and emotions. For instance, in November 2022, according to a survey conducted on 2,866 children and young people by the National Health Service, a UK-based government-funded healthcare system, around 18.0% of children aged 7 to 16 and 22.0% of young individuals aged 17 to 24 were found to potentially have a mental disorder in 2022. The rate of probable mental disorders among young people aged 17 to 19 rose from 17.4% in 2021 to 25.7% in 2022. Therefore, the rising prevalence of mental health disorders is driving the growth of the fluoxetine market.

Rising Healthcare Expenditure Drives Growth In The Fluoxetine Market

The increase in healthcare expenditure is expected to propel the growth of the fluoxetine market going forward. Healthcare expenditures are rising due to the increasing cost of advanced medical technologies, aging populations, and the prevalence of chronic diseases. Increased healthcare expenditure enhances the availability and affordability of medications such as fluoxetine, leading to improved access and adherence for patients needing treatment for depression and anxiety disorders. This can result in better overall mental health outcomes and reduced long-term healthcare costs. For instance, in January 2024, according to the National Institutes of Health, a US-based government agency, healthcare expenditure in the US rose by 4.1% in 2022 to reach $4.5 trillion, representing a faster growth rate compared to the 3.2% increase observed in 2021. Therefore, the increase in healthcare expenditure is driving the growth of the fluoxetine market.

Innovative Developments In The Fluoxetine Market
Major companies operating in the fluoxetine market are focusing on developing innovative products, such as fluoxetine tablets, to treat various mental health disorders, such as major depressive disorder. Fluoxetine tablets are pharmaceutical formulations containing fluoxetine hydrochloride, an antidepressant medication classified as a selective serotonin reuptake inhibitor (SSRI). For instance, in April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, announced the United States Food and Drug Administration (USFDA) approval for Fluoxetine Tabs 10 mg and 20 mg. The approval enhances the company's fluoxetine product line by introducing fluoxetine tablets alongside the already-approved capsules. Fluoxetine, classified as a selective serotonin reuptake inhibitor (SSRI), serves as an antidepressant medication utilized to treat conditions including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. The introduction of fluoxetine tablets expands the treatment options available within the company's fluoxetine portfolio, offering patients and healthcare providers additional flexibility and choices in managing these mental health disorders.

The fluoxetine market covered in this report is segmented -

1) By Dosage Form: Tablet, Solution, Capsule, Syrup, Other Dosage Forms
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Demographic: Adult, Pediatric, Geriatric
4) By Application: Obsessive-Compulsive Disorder, Panic Disorder, Depression, Bulimia Nervosa, Other Applications
5) By End User: Clinic, Hospital, Other End Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=16428&type=discount

Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC

Contents of the report:
1. Executive Summary
2. Fluoxetine Market Report Structure
3. Fluoxetine Market Trends And Strategies
4. Fluoxetine Market - Macro Economic Scenario
5. Fluoxetine Market Size And Growth
…..
27. Fluoxetine Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/fluoxetine-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.